Aberrant activation of the PI3K/AKT/mTOR pathway has been observed in critical subgroups of DLBCL samples, driven by chronic BCR signaling activation or loss of expression of phosphatases and PTEN (Xu et al. 2023). This evidence concerns the gene BCR and diffuse large B-cell lymphoma.